TraNsvenous TrIcuspid Valve ReplacemenT With LuX-Valve Plus System (TRINITY-US)
NCT06568003 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15
Last updated 2026-03-02
Summary
The LuX-Valve Plus System is intended for the treatment of patients with at least severe TR who are symptomatic and determined by a Heart Team not to be suitable for surgical treatment. This study aims to assess the safety and effectiveness of the LuX-Valve Plus System in high-surgical risk patients with at least severe tricuspid regurgitation (TR).
Conditions
- Tricuspid Regurgitation (TR)
Interventions
- DEVICE
-
Transcatheter Tricuspid Valve Intervention
Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.
Sponsors & Collaborators
-
Cardiovascular Research Foundation, New York
collaborator OTHER -
Jenscare Innovation Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-09-26
- Primary Completion
- 2025-10-02
- Completion
- 2030-10-31
- FDA Device
- Yes
Countries
- United States
Study Locations
More Related Trials
-
TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease
NCT05536310 ·Status: NOT_YET_RECRUITING
-
THE TRAVEL TRIAL: Transcatheter Right Atrial-ventricular Valve rEplacement With LuX-Valve
NCT04436653 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Tricuspid Valve Percutaneous Repair System in the Treatment of Severe Secondary Tricuspid Disorders
NCT04646811 ·Status: COMPLETED ·Phase: NA
-
TARGET 2.0 Study: Safety and Performance of the Cardiovalve TR Replacement System
NCT07334691 ·Status: RECRUITING ·Phase: NA
-
A Prospective, Multicenter, Randomized Controlled Trial to Evaluate the Efficacy and Safety of the Transcatheter Tricuspid Valvuloplasty System in Patients With Severe or Above Tricuspid Regurgitation
NCT05770648 ·Status: UNKNOWN ·Phase: NA
-
Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation
NCT06381271 ·Status: RECRUITING
-
The TRICURE EU Pivotal Study
NCT06581471 ·Status: RECRUITING ·Phase: NA
-
The JenaValve ALIGN-AR LVAD Registry
NCT06594705 ·Status: RECRUITING ·Phase: NA
-
Safety and Effectiveness Study of DragonFly-T System for Severe Tricuspid Regurgitation
NCT05556460 ·Status: RECRUITING ·Phase: NA
-
Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL)
NCT02387697 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation
NCT02536196 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects and High Risk Subjects Who Need Aortic Valve Replacement
NCT01531374 ·Status: COMPLETED ·Phase: NA
-
Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients
NCT02701283 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Evaluate the Transcatheter Artificial Aortic Valve and Transcatheter Artificial Heart Values Delivery System
NCT03788590 ·Status: UNKNOWN ·Phase: NA
-
MitraClip for Severe TR
NCT02863549 ·Status: UNKNOWN ·Phase: NA
-
ChAracterization of Patients and Treatment OUtcomes in Severe Tricuspid Regurgitation
NCT06838611 ·Status: RECRUITING
-
TRI-REPAIR: TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter System
NCT02981953 ·Status: COMPLETED ·Phase: NA
-
Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients
NCT02537769 ·Status: RECRUITING ·Phase: NA
-
TARGET Study: Safety and Performance of the Cardiovalve TR Replacement System
NCT05486832 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
German Registry for Transcatheter Tricuspid Valve Interventions
NCT04653428 ·Status: RECRUITING
-
Investigation of a Transcatheter Tricuspid Valved Stent Graft in Patients With Carcinoid Heart Disease
NCT05064514 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
J-Valve TF Early Feasibility Study
NCT06034028 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Comparison of a Single Versus Double Perclose Technique for TAVR
NCT06173115 ·Status: RECRUITING ·Phase: NA
-
International Multisite Transcatheter Tricuspid Valve Therapies Registry
NCT03416166 ·Status: RECRUITING
-
Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement
NCT01675440 ·Status: COMPLETED